These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32369828)

  • 1. Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse.
    Meinhardt MW; Güngör C; Skorodumov I; Mertens LJ; Spanagel R
    Neuropsychopharmacology; 2020 Jul; 45(8):1316-1322. PubMed ID: 32369828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories.
    Benvenuti F; Colombo D; Soverchia L; Cannella N; Domi E; Ciccocioppo R
    Psychopharmacology (Berl); 2023 Jul; 240(7):1521-1530. PubMed ID: 37266686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.
    Rouaud A; Calder AE; Hasler G
    J Psychopharmacol; 2024 Mar; 38(3):217-224. PubMed ID: 38214279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal Behavior in Psychedelic Research.
    Odland AU; Kristensen JL; Andreasen JT
    Pharmacol Rev; 2022 Oct; 74(4):1176-1205. PubMed ID: 36180111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats.
    Malikowska-Racia N; Koniewski M; Golebiowska J; Popik P
    J Psychopharmacol; 2023 Nov; 37(11):1149-1156. PubMed ID: 37842884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains.
    Varley TF; Carhart-Harris R; Roseman L; Menon DK; Stamatakis EA
    Neuroimage; 2020 Oct; 220():117049. PubMed ID: 32619708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
    Ezeaka UC; Kim HJJ; Laprairie RB
    Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
    Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR
    J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classic psychedelics and the treatment for alcoholism.
    Lodetti G; de Bitencourt RM; Rico EP
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Dec; 135():111129. PubMed ID: 39181308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.